Cartesian Therapeutics (RNAC) Research & Development (2016 - 2025)
Historic Research & Development for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $13.8 million.
- Cartesian Therapeutics' Research & Development rose 2107.02% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year decrease of 179.69%. This contributed to the annual value of $45.1 million for FY2024, which is 3670.36% down from last year.
- Per Cartesian Therapeutics' latest filing, its Research & Development stood at $13.8 million for Q3 2025, which was up 2107.02% from $14.9 million recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Research & Development high stood at $21.9 million for Q4 2023, and its period low was $9.7 million during Q1 2024.
- For the 5-year period, Cartesian Therapeutics' Research & Development averaged around $15.8 million, with its median value being $14.9 million (2025).
- As far as peak fluctuations go, Cartesian Therapeutics' Research & Development crashed by 4826.1% in 2024, and later surged by 5068.8% in 2025.
- Over the past 5 years, Cartesian Therapeutics' Research & Development (Quarter) stood at $20.3 million in 2021, then dropped by 6.65% to $19.0 million in 2022, then rose by 15.21% to $21.9 million in 2023, then tumbled by 48.26% to $11.3 million in 2024, then rose by 22.08% to $13.8 million in 2025.
- Its Research & Development was $13.8 million in Q3 2025, compared to $14.9 million in Q2 2025 and $14.7 million in Q1 2025.